Cynomolgus CD153 / CD30L / TNFSF8 Protein (Fc Tag)

Catalog Number: 90091-C01H



General Information

Gene Name Synonym:

TNFSF8

Protein Construction:

A DNA sequence encoding the cynomolgus TNFSF8 (G7P2F1) (Gln63-Asp234) was expressed, with the Fc region of human IgG1 at the N-terminus.

Source: Cynomolgus

Expression Host: HEK293 Cells

QC Testing

Purity: > 90 % as determined by SDS-PAGE

Bio Activity:

Immobilized Cynomolgus Fc-TNFSF8 at 10 μ g/ml (100 μ l/well) can bind biotinylated human CD30-Fch (Cat:10777-H03H), The EC₅₀ of biotinylated human CD30-Fch (Cat:10777-H03H) is 5.3-12.5 ng/ml.

Endotoxin:

< 1.0 EU per µg of the protein as determined by the LAL method

Stability:

Samples are stable for up to twelve months from date of receipt $% \left(1\right) =1$ at -70 $^{\circ}\mathrm{C}$

Predicted N terminal: Glu

Molecular Mass:

The recombinant cynomolgus TNFSF8 is a disulfide-linked homodimer. The reduced monomer comprises 432 amino acids and has a calculated molecular mass of 48.1 KDa.The apparent molecular mass of the protein is approximately 59 KDa respectively in SDS-PAGE.

Formulation:

Lyophilized from sterile PBS, pH 7.4

Normally 5 % - 8 % trehalose, mannitol and 0.01% Tween80 are added as protectants before lyophilization. Specific concentrations are included in the hardcopy of COA. Please contact us for any concerns or special requirements.

Usage Guide

Storage:


Store it under sterile conditions at -20° C to -80° C upon receiving. Recommend to aliquot the protein into smaller quantities for optimal storage.

Avoid repeated freeze-thaw cycles.

Reconstitution:

Detailed reconstitution instructions are sent along with the products.

SDS-PAGE:



Protein Description

CD30 ligand (CD30L), also known as CD153 and TNFSF8, is a membraneassociated glycoprotein belonging to the TNF superfamily and TNFR superfamily, and is a specific ligand for CD30/TNFRSF8 originally described as a cell surface antigen and a marker for Hodgkin lymphoma and related hematologic malignancies. CD30L is a type-II membrane glycoprotein expressed on activated T cells, stimulated monocytemacrophages, granulocytes, eosinophils, and some Burkitt-like lymphoma cell lines. CD30L is capable of transducing signals through CD30 on different CD30+ lymphoma cell lines, and mediates pleiotropic biologic effects including cell proliferation, activation, differentiation, as well as cell death by apoptosis. CD30-CD30 ligand interaction has been suggested to have a pathophysiologic role in malignant lymphomas, particularly Hodgkin disease, large cell anaplastic lymphomas and Burkitt lymphomas, and is also involved in activation and functioning of the T cell-dependent immune response. Thus, CD153 and its receptor CD30 are regarded as therapeutic targets in hematologic malignancies, autoimmune and inflammatory diseases.

References

1.Hargreaves PG, et al. (2002) Soluble CD30 binds to CD153 with high affinity and blocks transmembrane signaling by CD30. Eur J Immunol. 32(1): 163-73. 2.Blazar BR, et al. (2004) CD30/CD30 ligand (CD153) interaction regulates CD4+ T cell-mediated graft-versus-host disease. J Immunol. 173(5): 2933-41. 3.Oflazoglu E, et al. (2009) Targeting CD30/CD30L in oncology and autoimmune and inflammatory diseases. Adv Exp Med Biol. 647: 174-85.

Manufactured By Sino Biological Inc., FOR RESEARCH USE ONLY. NOT FOR USE IN HUMANS.

For US Customer: Fax: 267-657-0217 • Tel: 215-583-7898

Global Customer: Fax :+86-10-5862-8288
■ Tel:+86-400-890-9989
■ http://www.sinobiological.com